相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity
Naomi S. Rajapaksa et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma
Yun Chen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
PROTAC Technology: Opportunities and Challenges
Hongying Gao et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Multispecific drugs herald a new era of biopharmaceutical innovation
Raymond J. Deshaies
NATURE (2020)
Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges
Scott D. Edmondson et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Targeted protein degradation: elements of PROTAC design
Stacey-Lynn Paiva et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2019)
Targeting IRAK4 for Degradation with PROTACs
Joao Nunes et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88L265P Mutant Diffuse Large B Cell Lymphoma
Sebastien L. Degorce et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Targeted protein degradation: expanding the toolbox
Matthieu Schapira et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
PROTACs: great opportunities for academia and industry
Xiuyun Sun et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
Bing Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
Yonghui Sun et al.
CELL RESEARCH (2018)
Delineating the role of cooperativity in the design of potent PROTACs for BTK
Adelajda Zorba et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a dual role in myddosome formation and Toll-like receptor signaling
Dominic De Nardo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Mechanism of dysfunction of human variants of the IRAK4 kinase and a role for its kinase activity in interleukin-1 receptor signaling
Saurav De et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma
James S. Scott et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
The mechanism of activation of IRAK1 and IRAK4 by interleukin-1 and Toll-like receptor agonists
Stefan Vollmer et al.
BIOCHEMICAL JOURNAL (2017)
Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy
Priscilla N. Kelly et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Interleukin 1/Toll-like Receptor-induced Autophosphorylation Activates Interleukin 1 Receptor-associated Kinase 4 and Controls Cytokine Induction in a Cell Type-specific Manner
Leah Cushing et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Structure of the DDBI-CRBN E3 ubiquitin ligase in complex with thalidomide
Eric S. Fischer et al.
NATURE (2014)
IRAK4 Kinase As A Novel Therapeutic Target in the ABC Subtype of Diffuse Large B Cell Lymphoma
Kian-Huat Lim et al.
BLOOD (2012)
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo et al.
NATURE (2011)
分享论文
